Literature DB >> 12718713

An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.

Kathryn A Phillips1, David Veenstra, Stephanie Van Bebber, Julie Sakowski.   

Abstract

Methods of economic evaluation, especially cost-effectiveness analysis and cost-benefit analysis, are widely used to examine new healthcare technologies. However, few economic evaluations of pharmacogenomics have been conducted, and pharmacogenomic researchers may be unfamiliar with how to review or conduct these analyses. This review provides an overview of the methods of economic evaluation and examples of where they have been applied to pharmacogenomics. We discuss the steps in conducting a cost-effectiveness or cost-benefit analysis, demonstrating these steps using specific examples from the pharmacogenomics literature.

Mesh：

Year:  2003        PMID： 12718713     DOI： 10.1517/phgs.4.3.231.22691

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


  7 in total

Review 1.  Criteria influencing the clinical uptake of pharmacogenomic strategies.

Authors:  Jai Shah
Journal:  BMJ       Date:  2004-06-19

Review 2.  Bridging the Gaps in Personalized Medicine Value Assessment: A Review of the Need for Outcome Metrics across Stakeholders and Scientific Disciplines.

Authors:  William S Bush; Jessica N Cooke Bailey; Mark F Beno; Dana C Crawford
Journal:  Public Health Genomics       Date:  2019-08-27       Impact factor: 2.000

3.  Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.

Authors:  F Aminkeng; C J D Ross; S R Rassekh; L R Brunham; J Sistonen; M-P Dube; M Ibrahim; T B Nyambo; S A Omar; A Froment; J-M Bodo; S Tishkoff; B C Carleton; M R Hayden
Journal:  Pharmacogenomics J       Date:  2013-04-16       Impact factor: 3.550

Review 4.  A health services research agenda for cellular, molecular and genomic technologies in cancer care.

Authors:  Louise Wideroff; Kathryn A Phillips; Gurvaneet Randhawa; Anita Ambs; Katrina Armstrong; Charles L Bennett; Martin L Brown; Molla S Donaldson; Michele Follen; Sue J Goldie; Robert A Hiatt; Muin J Khoury; Graham Lewis; Howard L McLeod; Margaret Piper; Isaac Powell; Deborah Schrag; Kevin A Schulman; Joan Scott
Journal:  Public Health Genomics       Date:  2009-02-20       Impact factor: 2.000

Review 5.  Welfarism versus extra-welfarism: can the choice of economic evaluation approach impact on the adoption decisions recommended by economic evaluation studies?

Authors:  James Buchanan; Sarah Wordsworth
Journal:  Pharmacoeconomics       Date:  2015-06       Impact factor: 4.981

6.  Prevalence of polypharmacy and associated adverse health outcomes in adult patients with chronic kidney disease: protocol for a systematic review and meta-analysis.

Authors:  Ikechi G Okpechi; Mohammed M Tinwala; Shezel Muneer; Deenaz Zaidi; Feng Ye; Laura N Hamonic; Maryam Khan; Naima Sultana; Scott Brimble; Allan Grill; Scott Klarenbach; Cliff Lindeman; Amber Molnar; Dorothea Nitsch; Paul Ronksley; Soroush Shojai; Boglarka Soos; Navdeep Tangri; Stephanie Thompson; Delphine Tuot; Neil Drummond; Dee Mangin; Aminu K Bello
Journal:  Syst Rev       Date:  2021-07-04

7.  A critical analysis of barriers to the clinical implementation of pharmacogenomics.

Authors:  Ross A McKinnon; Michael B Ward; Michael J Sorich
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.